Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 9%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc is experiencing substantial revenue growth, with total revenue increasing by 84.7% year-over-year, driven primarily by a remarkable 117.2% rise in genomics revenue, which reached $252.9 million. The company's focus on emerging products, such as the xF liquid biopsy assay and the xT CDx test, is anticipated to yield higher average selling prices, enhancing both profitability and market position. Furthermore, the expected increase in test volumes following the anticipated reimbursement for the xM test presents a significant opportunity for further financial expansion in the near term.

Bears say

Tempus AI Inc has experienced a decline in gross margins in its Data & Other segment, dropping from 76.8% in Q3 2024 to 69.7% in Q3 2025, indicating potential challenges in maintaining profitability. The company has faced significant financial challenges, including substantial losses, existing debt of $518.8 million, and an operating cash flow decrease of $168.5 million year-over-year, raising concerns about its financial sustainability and ability to continue operations without additional funding. Furthermore, ongoing risks such as competition, regulatory hurdles, and potential declines in reimbursement rates may hinder its revenue growth and customer acquisition efforts.

TEM has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 9% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 11 analysts, TEM has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.